Summary
The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Notwithstanding major efforts in untangling its pathophysiology, we are not even close to reaching a cure. Despite available treatments, symptom control is generally suboptimal and hospitalisations and deaths remain at unacceptably high levels. This calls for disruptive innovation towards a long-term treatment strategy. Asthma is an inflammatory condition associated with immune deviations, most often atopic allergy. However, a key characteristic of asthma that remains relatively unexplored is susceptibility to infection. Most acute asthma attacks follow upper respiratory infections; infections are also associated with asthma initiation and persistence. Recent studies reveal that the respiratory microbiome is characteristically imbalanced (dysbiotic) in asthma. Our own data indicate that a feature of dysbiosis in asthma is reduced abundance of bacteriophages (phages). These bacterial viruses infect and are able to naturally control bacterial populations. Phage therapy has been grossly neglected in the western world and is currently just appearing as a novel tool against infection. However, it has never been used for rebalancing dysbiosis in humans.
We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma
We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/767015 |
| Start date: | 01-10-2017 |
| End date: | 31-03-2022 |
| Total budget - Public funding: | 2 971 750,00 Euro - 2 971 750,00 Euro |
Cordis data
Original description
The asthma pandemic imposes a huge burden on patients and health systems in both developed and developing countries. Notwithstanding major efforts in untangling its pathophysiology, we are not even close to reaching a cure. Despite available treatments, symptom control is generally suboptimal and hospitalisations and deaths remain at unacceptably high levels. This calls for disruptive innovation towards a long-term treatment strategy. Asthma is an inflammatory condition associated with immune deviations, most often atopic allergy. However, a key characteristic of asthma that remains relatively unexplored is susceptibility to infection. Most acute asthma attacks follow upper respiratory infections; infections are also associated with asthma initiation and persistence. Recent studies reveal that the respiratory microbiome is characteristically imbalanced (dysbiotic) in asthma. Our own data indicate that a feature of dysbiosis in asthma is reduced abundance of bacteriophages (phages). These bacterial viruses infect and are able to naturally control bacterial populations. Phage therapy has been grossly neglected in the western world and is currently just appearing as a novel tool against infection. However, it has never been used for rebalancing dysbiosis in humans.We propose that reinstating eubiosis within the asthmatic airway through phage therapy is feasible and will be able to control the immune dysregulation and clinical presentation of the disease. To achieve this, we must be able to predict the effects of adding phage mixtures to the complex ecology of the airways and design appropriate interventions. In CURE, we will develop a predictive model using information from virus-bacterial interactions, host responses and clinical disease expression, validated and fine-tuned using an in-vitro host-microbe-phage interface system. The project will develop phage preparations as candidates for clinical testing in asthma
Status
CLOSEDCall topic
FETOPEN-01-2016-2017Update Date
27-04-2024
Images
No images available.
Geographical location(s)
Search
Organisations
-
| ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON (Coördinator)
-
| ELIAVA BIO PREPARATIONS LTD
-
| EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING
-
| GIORGI ELIAVA INSTITUTE OF BACTERIOPHAGY, MICROBIOLOGY AND VIROLOGY
-
| IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
-
| MARIOS LYMARAKIS KAI SIA EE
-
| SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
-
| THE UNIVERSITY OF MANCHESTER
-
| UMEA UNIVERSITET
-
| UNIVERSYTET MEDYCZNY W LODZI.